Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children…
NCT00159913 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00159913 |
|---|---|
| Title | A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension. |
| Official title | A Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Parallel Group Study of Oral Sildenafil in the Treatment of Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension. |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Arterial Hypertension, Children |
| Intervention type | Drug |
| Interventions | Sildenafil citrate, Placebo |
| Enrollment | 235 |
| Start date | Aug 1, 2003 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Sep 12, 2005 |
| Last update posted | Feb 18, 2021 |
| Countries | Brazil, Canada, Chile, Colombia, Guatemala, Hungary, India, Italy, Japan, Malaysia, Mexico, Peru and 5 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: